Search
Alagebrium
go.drugbank.com/drugs/DB12497InvestigationalAlagebrium has been investigated for the treatment and prevention of Aging, Heart Failure, Physical Activity, Diabetic Nephropathy, and Cardiovascular Disease, among others.
Bifidobacterium Longum Infantis 35624
go.drugbank.com/drugs/DB17871ExperimentalBifidobacterium Longum Infantis 35624 is a probiotic being investigated for the treatment of gastrointestinal disorders, such as Crohn's disease and irritable bowel syndrome.[A259872, A259877]
Iopydol
go.drugbank.com/drugs/DB13389ApprovedWithdrawnCategories: Non-Watersoluble X-Ray Contrast Media, X-Ray Contrast Media, IodinatedUtatrectinib
go.drugbank.com/drugs/DB21295InvestigationalUtatrectinib is under investigation in clinical trial NCT01468324 (AZD7451 for Recurrent Gliomas). Utatrectinib has a monoisotopic molecular weight of 382.17 Da. … Utatrectinib is a small molecule drug. The usage of the INN stem '-trectinib' in the name indicates that Utatrectinib is a tropomyosin receptor kinase (TRK) inhibitor.
Metildigoxin
go.drugbank.com/drugs/DB13401InvestigationalCategories: Compounds used in a research, industrial, or household settingSodium apolate
go.drugbank.com/drugs/DB13477ExperimentalCategories: Compounds used in a research, industrial, or household settingBetadex
go.drugbank.com/drugs/DB03995InvestigationalCategories: Compounds used in a research, industrial, or household settingBecotatug
go.drugbank.com/drugs/DB19069InvestigationalBecotatug is under investigation in clinical trial NCT06380348 (JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung
Muvalaplin
go.drugbank.com/drugs/DB21568InvestigationalMuvalaplin is under investigation in clinical trial NCT05563246 (A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events). … Muvalaplin is a small molecule drug.
IDM-1
go.drugbank.com/drugs/DB05292ExperimentalIDM-1 is IDM’s most advanced antibody-based Cell drug for the treatment of cancer. … It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.